Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy.
Varo
E
E
Transplantation Unit, Hospital Clinico Universitario, 15706 Santiago de Compostela, Spain.
Padin
E
E
Otero
E
E
Tomé
S
S
Castroagudin
J F
JF
Delgado
M
M
Conde
R
R
Segade
F R
FR
Mella
C
C
González-Quintela
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007677:Kidney Function Tests; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology*; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D016559:Tacrolimus / Q000009:adverse effects*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D016559:Tacrolimus